click below
click below
Normal Size Small Size show me how
Pharmacology-PA
GI Lecture #1
| Question | Answer |
|---|---|
| 1. What are the factors influencing PUD? | Hydrochloric acid, pepsin, Alcohol, nicotine, Gastric mucosal ischemia, Helicobacter pylori, Ulcerogenic medications, Mucus secretion, Bicarbonate secretion |
| 2. What are the goals of treatment? | 1-Relieve pain, enhance healing, prevent complications, 2-Neutralize stomach acid, protect mucosa, prevent acid secretion, detect and eradicate H.pylori, 3-Avoid ulcerogenic drugs |
| 3. What are the agents employed against PUD? | 1-Antacids, 2-Histamine 2 Receptor Antagonists, 3-Proton Pump Inhibitors, 4-Anticholinergics, 5-Antimicrobials (H.pylori) |
| 4. What is the degree of Acid Inhibition to Heal an Ulcer? | It has been observed that a sustained increase in pH (> 4) would be sufficient to heal an ulcer |
| 5. What is one of the risk factors for refractory gastric ulcer? | The difficulty of maintaining gastric pH > 4 for a minimum daily period of 16 hr |
| 6. What is the Purpose of Inhibiting Gastric Acid Secretion in cases of Upper GI Bleeding? | In upper GI bleeding, the aim is to increase gastric pH in order to prevent acid degradation of the clot & accelerate healing as much as possible. |
| 7. Why is extremely potent inhibition required? | To achieve the intended results |
| 8. How should an ideal drug be to achieve a potent acid inhibition? | Ideal drug should be able to maintain pH > 4 for ≥ 16 hr/day |
| 9. In what cases is the ideal drug potent inhibition sufficient for? | Most refractory cases of peptic acid disease |
| 10. Can potent acid inhibition levels be achieved in all patients? | Yes |
| 11. Regardless of what three things in a patient can potent acid inhibition level be achieved? | Their basal acid secretion, metabolic capacity, or the presence of absence of H. pylori infection |
| 12. T/F Are Histamine 2 Receptor Antagonists a drug therapy for Treatment of PUD? | True |
| 13. What is the mechanism of action of Histamine 2 Receptor Antagonists? | It Competitively block the binding of histamine to H2 receptors →reduced intracellular cAMP concentrations →decreased secretion of gastric acid |
| 14. What are the Histamine 2 Receptor Antagonist? | (CFNR) 1-Cimetidine, 2-Famotidine, 3-Nizatidine, 4-Ranitidine |
| 15. What is the half-life and dosage of Cimetidine? | Cimetidine (Tagamet) half-life=2 hours (800mg QD or 400mg BID) |
| 16. What is the half-life of Famotidine? | Famotidine (Pepcid) half-life= 4 hours (40mg QD or 20mg BID) |
| 17. What is the half-life of Nizatidine? | Nizatidine (Axid) half-life= 2 hours (300mg QD or 150mg BID) |
| 18. What is the half-life of Ranitidine? | Ranitidine (Zantac) half-life= 3 hours (300mg QD or 150mg BID) |
| 19. Does H2-Receptors Antagonists produce 90% reduction in basal & food-stimulated secretion of gastric acid after single dose? | Yes |
| 20. Are H2 Receptor Antagonists somewhat less effective in reducing nocturnal secretion? | Yes |
| 21. What have studies demonstrated about H2 Receptor Antagonist? | Their effectiveness in promoting the healing of DU & GU, & preventing their recurrence |
| 22. Are various H2 receptor blockers equally effective in treating DU and GU? | Yes |
| 23. All H2RAs are safe in the treatment of? | dyspepsia and PUD. |
| 24. What are the differences between the various H2RAs? | Their cost and drug interaction profiles. |
| 25. Which drug out of Ranitidine v. Cimetidine has fewer adverse drug reactions, longer-lasting action, and ten times the activity of cimetidine? | Ranitidine |
| 26. Which drug out of Ranitidine v. Cimetidine has 10% the affinity that cimetidine has to P450 so it causes fewer side effects? | Ranitidine |
| 27. What H2 blockers have no CYP450 significant interactions? | Famotidine and Nizatidine |
| 28. What is the Famotidine activity? | 30X Cimetidine |
| 29. What is the equivalent of Nizatidine potency? | Ranitidine |
| 30. What is Dyspepsia? | chronic or recurrent pain in the upper abdomen or fullness with eating. |
| 31. What can dyspepsia be accompanied by? | bloating, belching, nausea or heartburn. |
| 32. What is the cause of dyspepsia? | May be due to gastroesophageal reflux disease (GERD) or gastritis > peptic ulcer disease (an ulcer of the stomach or duodenum) > cancer. |
| 33. In H2-Receptors Antagonists, What is the most important determinant of the rate of healing of duodenal ulcers? | Suppression of nocturnal acid secretion. |
| 34. What were the previous recommendations for H2RA agents? | Administer these agents at least twice a day |
| 35. In H2RA, is a single bedtime dose just as effective & elicit better compliance? | Yes |
| 36. When H2RA are administered for 6-8 weeks, what does H2 blockers promote? | H2 blockers promote healing of DU in 75% & 90% of cases respectively |
| 37. With appropriate dosages, what is the treatment duration of DU with H2RA in combination with H. pylori eradication therapy? | Approximately 4-8 weeks. |
| 38. What heals more slowly, GU or DU? | GUs heal more slowly than DUs, |
| 39. Which disease may require an increased duration of treatment of 8-12 weeks? | GU |
| 40. What is the pharmacokinetics of H2-Receptors Antagonists? | Rapidly absorbed 1-3 hrs to peak |
| 41. What drugs are hepatically metabolized? | Ranitidine & Cimetidine |
| 42. What drugs are renally metabolized? | Famotidine & Nizatidine |
| 43. Are dose adjustments required in renal & hepatic failure patients? | Yes |
| 44. What are the Side Effects of H2-Receptors Antagonists? | Usually minor and includes headache, dizziness, diarrhea, & muscular pain |
| 45. Are Hallucinations & confusion in elderly patients some of the side effects of H2RA? | Yes |
| 46. What drug is Hepatotoxicity associated with? | Ranitidine |
| 47. What drug elevates serum prolactin & alters estrogen metabolism in men? | Cimetidine |
| 48. Are Gynecomastia, Galactorrhea and reduced sperm count also some side effects of H2RA? | Yes |
| 49. What does the drug Cimetidine inhibit? | Inhibits many isozymes of the cytochrome P450 enzyme system |
| 50. What are the isozymes of cytochrome P450 enzyme system that leads to extensive drug interactions? | CYP1A2, CYP2C9, CYP2C19, CYP2D6, CYP2E1, and CYP3A4 |
| 51. What drugs have no effect on hepatic drug metabolism? | Famotidine & Nizatidine |
| 52. What combination with an H2 blocker has questionable rationale? | A combination with antacid |
| 53. What is not an appropriate combination with H2-R antagonist? | PPIs are not appropriate combination with H2-RA. |
| 54. What drug slows the microsomal metabolism of some drugs in a dose-dependent but in a reversible manner? | Cimetidine |
| 55. What does H2RA inhibit the metabolism of? | warfarin, diazepam & phenytoin, quinidine, theophylline, carbamazepine, imipramine |
| 56. What drug has less effect on hepatic enzymes? | Ranitidine |
| 57. What are the Proton Pump Inhibitors? | Omeprazole, esomeprazole, lansoprazole, pantoprazole, rabeprazole |
| 58. What is the MOA of PPI? | Binds irreversibly to the H+/K+-ATPase enzyme (proton pump) suppressing secretion of hydrogen ions into the gastric lumen |
| 59. Does PPI inhibit both basal and stimulated gastric acid secretion? | Yes |
| 60. Are PPIs dose-dependent? | Yes |
| 61. What do PPIs inhibit? | basal & food acid secretion |
| 62. What is the range in half-life of proton pump inhibitors? | 0.5–2 hours |
| 63. Is the effect of a single dose on acid secretion usually persists up to 2–3 days? | Yes |
| 64. Do PPIs inhibit the proteolytic activity of pepsin by increasing pH? | Yes |
| 65. What are Proton Pump Inhibitors (PPIs) used to treat? | Dyspepsia, Peptic ulcer disease (PUD), Gastroesophageal reflux disease (GERD), Laryngopharyngeal Reflux Disease, Barrett's esophagus, prevention of stress gastritis, Gastrinomas and other conditions that cause hypersecretion of acid, Zollinger-Ellison syn |
| 66. T/F Proton Pump Inhibitors (PPIs) are among the most widely-selling drugs in the world as a result of their efficacy and safety? | True |
| 67. What are the 1st Generation PPI agents? | Omeprazole, Lansoprazole, Pantoprazole |
| 68. What are the 2nd Generation PPI agents? | Rabeprazole, Esomeprazole |
| 69. What is Esomeprazoie? | Esomeprazole is the S isomer of omeprazole |
| 70. Does Esomeprazoie undergoes less first-pass metabolism in the liver? | Yes |
| 71. Does Esomeprazoie have a lower plasma clearance as compared with omeprazole? | Yes |
| 72. Do PPIs undergo extensive first-pass metabolism in the liver, resulting in various inactive metabolites that are excreted in the urine or bile? | Yes |
| 73. What are PPIs Metabolized by? | The cytochrome P450 system (mainly by isoenzymes CYP2C19 & CYP3A4) |
| 74. What are the two generations of PPI? | “old” and “new” generations |
| 75. What generation has substantial inter-patient variability in pharmacokinetics? | First “old” generation PPIs |
| 76. Does the First “old” generation PPIs have significant interactions with other drugs (CYP 2C19)? | Yes |
| 77. What does the time of dosing and ingestion of meals influence? | Their pharmacokinetics and their ability to suppress gastric acid secretion. |
| 78. What generation has a relatively slow onset of pharmacological action? | First “old” generation PPIs |
| 79. Are first “old” generation PPIs limited in their usefulness in on-demand therapy? | Yes |
| 80. Are several doses required to achieve maximum acid suppression in first “old” generation PPIs? | Yes |
| 81. Which generation of PPIs fail to provide 24-h suppression of gastric acid? | First “old” generation PPIs |
| 82. Does first “old” generation PPIs have nocturnal acid breakthrough even with twice-daily dosing? | Yes |
| 83. In “new” generation of PPI, what drugs achieve more rapid and profound inhibition? | Rabeprazole and esomeprazole |
| 84. Does “new” generation of PPI, provide acid control and symptom relief over 24 h? | Yes |
| 85. In “new” generation of PPI, what is there a balanced metabolism of? | Rabeprazole |
| 86. In “new” generation of PPI, what does the metabolism of Rabeprazole involve? | Both cytochrome P450 (CYP)-mediated reactions and non enzymatic reactions. |
| 87. In “new” generation of PPI, where does the cytochrome P450 (CYP)-mediated reactions occur? | In the liver |
| 88. In “new” generation of PPI, what does a non enzymatic reaction mean? | Genetic polymorphisms for CYP 2C19 |
| 89. In “new” generation of PPIs, does genetic polymorphisms for CYP 2C19 not significantly influence rabeprazole clearance and clinical efficacy? | True |
| 90. What drug is not complicated by clinically significant drug-drug interaction? | Rabeprazole |
| 91. What drug is complicated by clinically significant drug-drug interactions? | Esomeprazole |
| 92. T/F PPI Inhibition of acid secretion is more pronounced than with H2RAs? | True |
| 93. What does the irreversible binding of PPI result in? | Prolonged inhibition of gastric acid secretion. |
| 94. T/F PPIs require an acid environment to be effective? | True |
| 95. Due to PPIs need of acid environment, should they be used with other antisecretory agents? | No |
| 96. When is the dose administered effect of PPIs more effective? | Doses administered in the morning result in a higher median 24-hour pH effect than if given at night. |
| 97. In what situations are PPIs more effective? | PPIs are effective adjuncts in the eradication of H. pylori (inhibition of the parasites urease activity) |
| 98. What is the treatment duration of PUD with PPIs during appropriate dosages? | Approximately 4-8 weeks. |
| 99. Are there any evidence to show that PPIs have direct toxic effects? | No |
| 100. What are the most common adverse reactions of PPIs? | episodes of diarrhea, nausea, abdominal pain, dizziness, headache, or skin rash |
| 101. How are the manifestations of PPIs? | Most often transient & moderate in severity, not requiring reductions in compound dosage |
| 102. In a patient continuously taking PPIs, what deficiency can be apparent? | A mild vitamin B12 deficiency has been seen as the result of decreased vitamin absorption |
| 103. What is the reason for the B12 deficiency in patients using B12? | This is due to impaired release of the vitamin from food, because this is a process enhanced by the presence of an intragastric acid environment |
| 104. What should be the time of administration of PPIs? | Should be administered after fasting (new pumps synthesized overnight) & before a meal so that at the time the peak plasma concentration is reached, there is also a maximum of proton pumps activated (i.e.secreting acid) |
| 105. For treatments of DU & GU, how long should PPIs be used? | Should be used for 4-6 weeks |
| 106. How can PPIs have a Short Half-life & a Long-lasting Effect? | Despite their short half-life, PPIs exert a persistent pharmacological action b/c they irreversibly binding to the proton pump so they render the necessary synthesis of new enzymes to re-establish gastric acid secretion |
| 107. What is recommended in patients with severe liver failure? | A decrease in the usual dose of these drugs is recommended in this group of patients |
| 108. In patients with severe liver failure, what occurs in the area under the plasma curve for PPIs? | It increases 7-9 folds |
| 109. In patients with severe liver failure, what happens to the half-life after the PPIs increase 7-9 folds? | Their half-life is prolonged to 4-8 hr. |
| 110. Should PPIs influence on phenytoin, carbamazepine, warfarin, & diazepam be monitored? | Yes |
| 111. Confirmed by a recent analysis of cases recorded by (FDA), what are the clinical impact of these interactions? | It is very low (rates lower than -0.2 per 1,000,000 prescriptions), with no differences between the different PPIs |
| 112. How does the Presence of H. Pylori influence Degree of Acid inhibition? | PPIs show a decreased efficacy in patients not infected by H. pylori. |
| 113. What is required for a patient not infected by H. pylori? | Due to the decreased efficacy in patients not infected with H. pylori, it requires the use of higher doses of the PPI |
| 114. Do PPIs Have Direct Action on H.Pylori? | PPIs inhibit the urease protecting H. pylori from acid |
| 115. How does PPIs work alone? | PPIs alone only achieve eradication in 10-15% of cases. |
| 116. Do PPI Promote Actions of Antibiotics in H. Pylori Eradication? | PPIs have synergistic effects with several antimicrobial agents |
| 117. What drug increases amoxicillin levels in gastric juices and improve H. pylori cure rate when given with amoxicillin? | High dose omeprazole |
| 118. How does clarithromycin activity work against H. pylori? | It enhances as gastric pH increases |